Mylan's anti-Tuberculosis drug Delamanid's treatment will be limited to those patients who have stopped responding to most of first and second line of treatment.
Indian unit of US drug maker Mylan Inc. has received approval from the country's drug regulator DCGI to market Delamanid, a new class of anti Tuberculosis (TB) medicine discovered to specifically treat Multi Drug Resistant TB (MDR) in India.
Like Bedaquiline, which was the first TB drug launched in 40 years in 2016, Delamanid's treatment will be "limited" to those patients who have stopped responding to most of first and second line of treatment. The drug billed as "wonder drug" will be rolled out in government-run-TB programme. Prior to this, the ministry of health and family welfare had in 2016 launched Bedaquiline drug for treatment of drug resistant TB for 600 patients across India. It was made available in five cities-Delhi, Chennai, Mumbai, Guwahati and Ahmedabad.
With cases of multi drug resistant (MDR) and extensively drug resistant (XDR) TB rising in India, the new drug-Delamanid 50mg could benefit large number of people suffering from the infectious disease.